首页|骨髓微环境中CXC趋化因子配体8介导急性髓系白血病发生、发展的调控机制与临床意义

骨髓微环境中CXC趋化因子配体8介导急性髓系白血病发生、发展的调控机制与临床意义

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
  • 维普
目的:通过检测不同病情阶段急性髓系白血病(AML)患者CXC趋化因子配体8(CXCL8)的水平变化,分析其与AML患者临床病情及预后的关联性,探索骨髓微环境中CXCL8对白血病发生、发展及恶性生物学行为的调控机制,为AML的基础研究和临床诊治提供借鉴与参考.方法:收集不同病情阶段AML患者骨髓标本,采用ELISA检测CXCL8含量;利用实时荧光定量PCR(qRT-PCR)检测不同AML细胞系中CXCL8特异性受体CXCR1/2表达情况;选取U937细胞为AML疾病模型,给予不同浓度外源性rCXCL8干预U937细胞,观察细胞形态学变化,并利用CCK-8法检测细胞增殖,qRT-PCR检测CXCR1/2表达变化;将初诊AML患者BM-MSC与U937细胞共培养,ELISA检测共培养体系CXCL8变化差异;Annexin V/PI双染流式细胞术分别检测rCXCL8、anti-CXCL8对U937细胞凋亡的影响,Western blot揭示其间伴随的分子机制.结果:初诊及复发AML患者CXCL8水平显著高于健康者(P<0.05),复发阶段CXCL8水平显著高于其他病情阶段(P<0.01),而与健康者相比,CR阶段且无感染的AML患者CXCL8水平差异无统计学意义(P>0.05).BM-MSC与U937细胞共培养体系中CXCL8含量及其共培养体系下U937细胞CXCL8 mRNA水平均显著高于未加入BM-MSC的单培养Mono组(P<0.05).利用rCXCL8干预U937细胞可通过上调Bcl-2表达并下调Bax表达促进细胞增殖,并上调CXCL8特异性受体CXCR1/2表达.通过拮抗CXCL8(anti-CXCL8)后,上调Bax表达并下调Bcl-2表达同时抑制ERK1/2信号通路活化水平诱发U937细胞凋亡.结论:CXCL8与AML病情、预后转归密切相关,是AML患者疾病进展、预后评估的有效监测指标.骨髓微环境中CXCL8是介导白血病细胞恶性增殖、免疫逃逸的重要趋化因子,通过拮抗CXCL8可诱导U937细胞发生凋亡,其机制可能与Bcl-2家族蛋白表达变化、抑制ERK1/2信号通路活化水平有关.
Regulatory mechanism and clinical significance of CXC chemokine ligand 8 in bone marrow microenvironment mediating occurrence and development of acute myeloid leukemia
Objective:By detecting the level changes of CXC chemokine ligand 8(CXCL8)in acute myelogenous leukemia(AML)patients at different disease stages,to analyze its correlation with the clinical condition and prognosis of AML patients,and to explore the effect of CXCL8 in the bone marrow microenvironment on the occurrence and development of AML and the regulatory mech-anism of malignant biological behavior of AML cell lines,to provide novel reference for the basic research and clinical diagnosis and treatment of AML.Methods:Bone marrow specimens from AML patients at different disease stages were collected,and ELISA was used to detect the content of CXCL8;quantitative real-time PCR(qRT-PCR)was used to detect the expression of CXCL8-specific receptor CXCR1/2 in different AML cell lines.U937 cells were selected as the AML disease model,and different concentrations of exogenous rCXCL8 were intervened in U937 cells,and the morphological changes of the cells were observed under the microscope.BM-MSCs from newly diagnosed AML patients were co-cultured with U937 cells,and ELISA was used to detect the difference in the content of CXCL8 in the co-culture system;Annexin V/PI double staining flow cytometry was used to detect the effects of rCXCL8 and anti-CXCL8 on the apoptosis of U937 cells respectively,and Western blot was used to reveal the accompanying molecular protein mechanism.Results:The level of CXCL8 in newly diagnosed and relapsed AML patients was significantly higher than that in healthy people(P<0.05),the level of CXCL8 in relapsed stage of AML was significantly higher than that in other disease stages of AML(P<0.01),and the level of CXCL8 in AML patients with CR stage and no infection was significantly higher than that in healthy people(P>0.05).The content of CXCL8 in the co-culture system of BM-MSC and U937 cells and the level of CXCL8 mRNA in U937 cells in the co-culture system were significantly higher than those in the monoculture group without BM-MSC(P<0.05).Intervention of rCXCL8 in U937 cells could promote cell proliferation by up-regulating Bcl-2 expression and down-regulating Bax expression,and up-regulate the expression of CXCL8-specific receptors CXCR1/2.After antagonizing CXCL8(anti-CXCL8),it will induce U937 cell apoptosis by up-regulating of Bax expression and down-regulating of Bcl-2 expression while inhibiting the activation level of ERK1/2 signaling pathway.Conclusion:CXCL8 is closely related to the disease and prognosis of AML,and is an effective monitoring indicator for disease pro-gression and prognosis evaluation of AML patients.CXCL8 in the bone marrow microenvironment is an important chemokine for malig-nant proliferation and immune escape of leukemia cells.By antagonizing CXCL8,U937 cells can be induced to undergo apoptosis,whose mechanism may be related to the expression changes of Bcl-2 family proteins and the inhibition of ERK1/2 signaling pathway activation.

Acute myelogenous leukemiaCXC chemokine ligand 8CXC chemokine receptor 1CXC chemokine receptor 2Malignant biological behaviorOncogenic mechanismPrognosis

刘彦权、殷悦、唐焕文

展开 >

广东医科大学附属东莞第一医院血液科,东莞 523808

福建医科大学附属协和医院血液科,福州 350001

急性髓系白血病 CXC趋化因子配体8 CXC趋化因子受体1 CXC趋化因子受体2 恶性生物学行为 致癌机制 预后

国家自然科学基金面上项目广东省教育厅高等学校特色创新项目广东医科大学学科建设项目

820735822020KTSCX0484SG21209G

2024

10.3969/j.issn.1000-484X.2024.01.022

中国免疫学杂志
中国免疫学会,吉林省医学期刊社

中国免疫学杂志

CSTPCD北大核心
影响因子：0.926
ISSN：1000-484X
年,卷(期)：2024.40(1)
  • 25